Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2029

Conditions
Small Cell Neuroendocrine Carcinoma of BladderBladder CancerUrothelial Carcinoma Bladder
Interventions
DRUG

Atezolizumab

Atezolizumab 20 mL (1200 mg) on Day 1, once every 3 weeks for up to 20 cycles (each cycle = 21 days)

DRUG

Carboplatin

Carboplatin AUC 5 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).

DRUG

Cisplatin

Cisplatin 70 mg/m2 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).

DRUG

Etoposide

Etoposide 100 mg/m2 IV on Days 1 - 3 every cycle for the first 4 cycles (each cycle = 21 days)

PROCEDURE

Cystectomy

Cystectomy should be performed within 42 days after completion of last administered study therapy of induction phase (first 4 cycles of chemotherapy).

Trial Locations (2)

20016

RECRUITING

Johns Hopkins University: Sibley Memorial Hospital, Washington D.C.

21287

RECRUITING

Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER